Hengrui Pharma Nine-Month Profit Rises on Out-Licensing Gains
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Oshkosh Cuts 2026 Outlook as Quarterly Operating Income Falls 24.3%
Oshkosh lowered its 2026 outlook due to reduced fire truck manufacturing throughput and reported a 24.3% decline in quarterly operating income. Its shares fell 6.4% in morning trad
M impact | EARNINGS | Oct 29, 2026, 03:16 PM UTC
Ford Raises Low End of 2026 Adjusted EBIT Outlook
Ford now expects 2026 adjusted EBIT of $10.5 billion to $11 billion, up from $10 billion to $11 billion, and targets 8% adjusted EBIT margins by 2029.
M impact | EARNINGS | Oct 29, 2026, 03:16 PM UTC
T-Mobile Raises 2026 Free Cash Flow Outlook After Strong Quarter
T-Mobile raised its full-year free cash flow outlook, citing postpaid account growth, higher average revenue per account and expanding margins. It expects 2026 service revenue of a
M impact | EARNINGS | Oct 29, 2026, 03:16 PM UTC
Dis-Chem Pharmacies HEPS falls 12.8% to 64.3 cents
Headline earnings per share for the six months ended Aug. 31, 2026, fell 12.8% to 64.3 cents.
M impact | EARNINGS | Oct 29, 2026, 03:15 PM UTC
Dis-Chem Pharmacies Six-Month Revenue Rises 8% to R23 Billion
Group revenue increased 8.0% for the six months ended August 31, 2026.
M impact | EARNINGS | Oct 29, 2026, 03:15 PM UTC
Xerox Shares Fall 40.3% After Loss, Outlook Cuts and Dividend Suspension
Xerox reported a third-quarter GAAP net loss of $1.02 billion, cut its full-year profit and cash flow outlook, and suspended its dividends to preserve liquidity.
M impact | EARNINGS | Oct 29, 2026, 03:15 PM UTC